Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMA

The DJS Law Group announces that it is investigating claims on behalf of investors of Olema Pharmaceuticals, Inc. (“Olema” or “the Company”) (NASDAQ: OLMA) for violations of the securities laws.

INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. Olema is the subject of an Investor’s Business Daily report published on March 9, 2026. According to the report, the failure of a Roche trial for an oral breast cancer medication points to issues with Olema’s competing medication. According to analyst Matthew Biegler, the Roche results "comes with a dent to the thesis that oral SERDs can win in front-line breast cancer." Based on this news, shares of Olema fell by more than 19.6% in morning trading on the same day.

If you are a shareholder who suffered a loss, contact us to participate.

WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260309730374/en/

The Olema Pharmaceuticals Stock at the time of publication of the news with a fall of -21,90 % to 16,83USD on Nasdaq stock exchange (09. März 2026, 18:45 Uhr).